€100M Mandate Awarded to Groupe Financiere Hottinger & Co. Ltd
Groupe Financiere Hottinger & Co. Ltd (Hottinger) the London-based company which provides portfolio management and advisory services, today announced that they had been awarded a €100m mandate by an international family following months of rigorous appraisal.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160419006057/en/
The mandate includes discretionary investment management and brokerage agreements.
Hottinger is a leading, London-based boutique Investment Manager which has provided investment solutions to UK and international clients since 2001. Their clients are mostly sophisticated private individuals but also include charities, trusts and institutions.
Frédéric Hottinger, the respected banker and senior representative of the Hottinger family still plays an active role in promoting the family brand, which has a history spanning four centuries of service as financiers and bankers to the nobility and wealthy families of Europe.
Mr Hottinger commented he expects the business to grow substantially over the next few years as more international families with complex wealth management requirements seek the comfort of internationally experienced wealth management advice that is enshrined in the robust UK domestic regulatory regimes.
Groupe Financiere Hottinger & Co. Ltd
+ 44 207 227 3400
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
CA-TRUE-RELIGION19.10.2018 19:39 | pressemeddelelse
Manchester United and True Religion Launch Denim Range
ARCH-INSURANCE19.10.2018 15:12 | pressemeddelelse
Arch Insurance Announces Strategic Leadership Changes
MA-TAKEDA-PHARMACEUTICAL19.10.2018 14:02 | pressemeddelelse
Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer
VERTEX-PHARMACEUTICALS19.10.2018 13:56 | pressemeddelelse
Vertex Receives European CHMP Positive Opinion for KALYDECO® (ivacaftor) to Treat Patients With Cystic Fibrosis Aged 12 to <24 months With Certain Mutations in the CFTR Gene
TX-SCHLUMBERGER-LIMITED19.10.2018 13:02 | pressemeddelelse
Schlumberger Announces Third-Quarter 2018 Results
CA-TRADESHIFT19.10.2018 13:02 | pressemeddelelse
Tradeshift Announces Q3 2018 Results
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum